Illumina’s revenue was flat for the third quarter as the sequencing giant continues to deal with headwinds from a China sales ...

Q3 2025 Management View CEO Jacob Thaysen reported, "In the third quarter, we delivered another strong performance with ...

Illumina aims to transform human health practices through its leadership of genomic sequencing and related applications. The firm provides a broad range of instruments and related consumables to help ...

Illumina this month named Mark Field as its next Chief Information Officer, adding a veteran technology and R&D executive to its leadership team as the DNA sequencing giant navigates the next wave of ...

Illumina's up-and-coming constellation innovation delivers accuracy, speed, and ease of use in trial by GeneDx Constellation outperformed orthogonal methods in identifying select difficult-to-map ...

Genomics has administered a double dose of litigation to Illumina, joining with separate partners in a pair of federal lawsuits accusing the sequencing giant of infringing on nine patents related to ...

Illumina is rated a BUY as it drives growth with AI, multiomics, and strategic acquisitions. Click here to read my earnings ...

Illumina is diving deeper into proteomics research with a $425 million plan to acquire SomaLogic, including its protein analysis platforms and certified lab services business. The deal with ...

"Illumina has inflicted substantial harm on Element, resulting in lost sales, diminished market share, and reduced profits," counsel for DNA-sequencing company Element Biosciences Inc. alleged in an ...

Sept 22 (Reuters) - Life sciences company Element Biosciences sued Illumina (ILMN.O), opens new tab on Monday in separate cases in federal courts in California and ...